GREENLAND MINES LTD Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GREENLAND MINES LTD stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.75K, a 99.98% decline year-over-year.
- GREENLAND MINES LTD stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $9.86M.
- GREENLAND MINES LTD stock issued during period, value, stock options exercised for the quarter ending 2023-03-31 was -$631.70K.
- GREENLAND MINES LTD stock issued during period, value, stock options exercised for the quarter ending 2022-06-30 was $115.00M.
- GREENLAND MINES LTD stock issued during period, value, stock options exercised for fiscal 2025 was $9.86M.
- GREENLAND MINES LTD stock issued during period, value, stock options exercised for fiscal 2022 was $115.00M.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.75K 10-Q · filed 2026-08-17 | |
| 2025-12-31 | $9.86M 10-K/A · filed 2026-08-14 | |
| 2025-06-30 | $9.86M 10-Q · filed 2026-08-17 | |
| 2023-03-31 | -$631.70K 10-Q · filed 2023-05-24 | |
| 2022-12-31 | $115.00M 10-K/A · filed 2023-10-18 | |
| 2022-06-30 | $115.00M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |